Abstract
Abstract
Ischemic stroke is one of the most severe neurological disorders with limited therapeutic strategies. The utilization of nanoparticle drug delivery systems is a burgeoning field and has been widely investigated. Among these, biomimetic drug delivery systems composed of biogenic membrane components and synthetic nanoparticles have been extensively highlighted in recent years. Biomimetic membrane camouflage presents an effective strategy to prolong circulation, reduce immunogenicity and enhance targeting. For one thing, biomimetic nanoparticles reserve the physical and chemical properties of intrinsic nanoparticle. For another, the biological functions of original source cells are completely inherited. Compared to conventional surface modification methods, this approach is more convenient and biocompatible. In this review, membrane-based nanoparticles derived from different donor cells were exemplified. The prospect of future biomimetic nanoparticles in ischemic stroke therapy was discussed.
Graphic abstract
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
1 Department of Neurosurgery, Shandong Provincial Hospital, Shandong University, 250021, Jinan, China (GRID: grid.27255.37) (ISNI: 0000 0004 1761 1174)
2 Department of Endocrinology, Qilu Hospital, Cheeloo College of Medicine, Shandong University, 250012, Jinan, China (GRID: grid.27255.37) (ISNI: 0000 0004 1761 1174)
3 Department of Neurosurgery, Shandong Provincial Qianfoshan Hospital, Shandong University, 250021, Jinan, China (GRID: grid.27255.37) (ISNI: 0000 0004 1761 1174)
4 Department of Neurosurgery, The First Affiliated Hospital of Shandong First Medical University and Shandong Provincial Qianfoshan Hospital, 250014, Jinan, China (GRID: grid.452422.7) (ISNI: 0000 0004 0604 7301)
5 Shandong Key Laboratory of Reproductive Medicine, Department of Obstetrics and Gynecology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, 250021, Jinan, Shandong, China (GRID: grid.410638.8) (ISNI: 0000 0000 8910 6733)
6 Department of Neurosurgery, Shandong Provincial Qianfoshan Hospital, Shandong University, 250021, Jinan, China (GRID: grid.27255.37) (ISNI: 0000 0004 1761 1174); Department of Neurosurgery, The First Affiliated Hospital of Shandong First Medical University and Shandong Provincial Qianfoshan Hospital, 250014, Jinan, China (GRID: grid.452422.7) (ISNI: 0000 0004 0604 7301); Medical Science and Technology Innovation Center, Shandong First Medical University and Shandong Academy of Medical Sciences, 250117, Jinan, China (GRID: grid.410587.f)